Jennifer Clemens v. Execupharm Inc

48 F.4th 146
CourtCourt of Appeals for the Third Circuit
DecidedSeptember 2, 2022
Docket21-1506
StatusPublished
Cited by78 cases

This text of 48 F.4th 146 (Jennifer Clemens v. Execupharm Inc) is published on Counsel Stack Legal Research, covering Court of Appeals for the Third Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Jennifer Clemens v. Execupharm Inc, 48 F.4th 146 (3d Cir. 2022).

Opinion

PRECEDENTIAL

UNITED STATES COURT OF APPEALS FOR THE THIRD CIRCUIT ____________

No. 21-1506 ____________

JENNIFER CLEMENS, Appellant

v.

EXECUPHARM INC.; PAREXEL INT’L CORP. ____________

On Appeal from the United States District Court for the Eastern District of Pennsylvania (Civil No. 2-20-cv-03383) District Judge: Honorable Gerald J. Pappert ____________

Argued December 14, 2021 ____________

Before: GREENAWAY, JR., KRAUSE, and PHIPPS, Circuit Judges.

(Filed: September 2, 2022) Mark S. Goldman Goldman Scarlato & Penny 161 Washington Street 8 Tower Bridge, Suite 1025 Conshohocken, PA 19428

J. Austin Moore [ARGUED] Norman E. Siegel Barrett J. Vahle Caleb J. Wagner Stueve Siegel Hanson 460 Nichols Road Suite 200 Kansas City, MO 64112

Counsel for Appellant

Shifali Baliga Kristine M. Brown Donald M. Houser [ARGUED] Alston & Bird 1201 West Peachtree Street One Atlantic Center, Suite 4900 Atlanta, GA 30309

Mathieu Shapiro Obermayer Rebmann Maxwell & Hippel 1500 Market Street Centre Square West, 34th Floor Philadelphia, PA 19102

Counsel for Appellees

2 ____________

OPINION OF THE COURT ___________

GREENAWAY, JR., Circuit Judge.

In this appeal, Jennifer Clemens asks us to reverse the District Court’s dismissal of her complaint seeking equitable and monetary relief in connection with a data breach that resulted in the publication of her sensitive personal information on the Dark Web. Clemens argues that her injury was sufficiently imminent to constitute an injury-in-fact for purposes of standing. We agree. Accordingly, we will vacate the judgment of the District Court and remand for consideration of the merits.

I. Background1

Clemens is a former employee of ExecuPharm, Inc. (“ExecuPharm” or “the Company”), a subsidiary of the global biopharmaceutical company Parexel International Corp. (“Parexel”). As a condition of her employment, Clemens was required to provide ExecuPharm with sensitive personal and financial information, including her address, social security

1 Where, as here, the challenge to a District Court’s subject matter jurisdiction was made on the face of the pleadings, we accept all “well-pleaded factual allegations as true and draw all reasonable inferences” in favor of the plaintiff. In re Horizon Healthcare Servs. Inc. Data Breach Litig., 846 F.3d 625, 633 (3d Cir. 2017).

3 number, bank and financial account numbers, insurance and tax information, her passport, and information relating to her husband and child. In exchange, Clemens’s employment agreement provided that ExecuPharm would “take appropriate measures to protect the confidentiality and security” of this information. J.A. 41 ¶ 58. Based on the complaint’s allegations, ExecuPharm did not perform its obligation.

After Clemens had left ExecuPharm, a hacking group known as CLOP accessed ExecuPharm’s servers through a phishing attack in March 2020, stealing sensitive information pertaining to current and former employees, including Clemens. Specifically, the stolen information contained social security numbers, dates of birth, full names, home addresses, taxpayer identification numbers, banking information, credit card numbers, driver’s license numbers, sensitive tax forms, and passport numbers. In addition to exfiltrating the data, CLOP installed malware to encrypt the data stored on ExecuPharm’s servers. Then, CLOP held the decryption tools for ransom, threatening to release the information if ExecuPharm did not pay the ransom. Either because ExecuPharm refused to pay or for nefarious reasons unknown, the hackers made good on their threat and posted the data on underground websites located on the Dark Web, which is “a portion of the Internet that is intentionally hidden from search engines and requires the use of an anonymizing browser to be accessed. It is most widely used as an underground black market where individuals sell illegal products like . . . sensitive stolen data that can be used to commit identity theft or fraud.” J.A. 25 ¶ 15. Screenshots by an Israel-based intelligence firm confirm that CLOP made available for download at least one archive containing nearly 123,000 files and 162 gigabytes of

4 data pertaining to ExecuPharm and Parexel, including sensitive employee information.

Throughout March and April of 2020, ExecuPharm provided periodic updates to current and former employees to inform them of the breach and encourage them to take precautionary measures. ExecuPharm appreciated the risks, cautioning current and former employees that “[u]nauthorized access to [the compromised] information may potentially lead to the misuse of [their] personal data to impersonate [them] and/or to commit, or allow third parties to commit, fraudulent acts such as securing credit in [their] name.” J.A. 30 ¶ 28.

To mitigate potential harm, Clemens took immediate action. She conducted a review of her financial records and credit reports for unauthorized activity; placed fraud alerts on her credit reports; transferred her account to a new bank; enrolled in ExecuPharm’s complimentary one-year credit monitoring services; and purchased three-bureau credit monitoring services for herself and her family for $39.99 per month for additional protection. As a result of the breach, Clemens alleges that she has sustained a variety of injuries— primarily the risk of identity theft and fraud—in addition to the investment of time and money to mitigate potential harm.

Seeking redress, Clemens brought suit against ExecuPharm and Parexel in the United States District Court for the Eastern District of Pennsylvania. She sought to represent herself and a class of all others whose personal information was compromised, as well as a subclass of current and former ExecuPharm employees whose employment agreements promised that the Company would take appropriate measures to protect their personal data. She invoked the subject matter

5 jurisdiction of the District Court under the Class Action Fairness Act, 28 U.S.C. § 1332(d).

She asserted claims for negligence (Count I), negligence per se (Count II), and breach of implied contract (Count III) against both Defendants. She also asserted claims for breach of contract (Count IV), breach of fiduciary duty (Count V), and breach of confidence (Count VI) against ExecuPharm. Lastly, she sought a declaratory judgment that Defendants’ existing data security measures fail to comply with their fiduciary duties of care and that instructs them to implement and maintain industry-standard measures.

ExecuPharm and Parexel filed a motion to dismiss the complaint under Federal Rule of Civil Procedure 12(b)(6). The District Court ordered the parties to submit supplemental briefing regarding Clemens’s standing, and, after receiving that briefing, granted the motion to dismiss on February 25, 2021 based on lack of Article III standing. Specifically, the District Court stated that it sought to follow our “bright line” rule providing that allegations of an increased risk of identity theft resulting from a security breach are insufficient for standing. J.A. 9 (quoting In re Rutter’s Inc. Data Sec. Breach Litig., 511 F. Supp. 3d 514, 525 (M.D. Pa. 2021)). Applying our decision in Reilly v. Ceridian Corp., 664 F.3d 38 (3d Cir. 2011), the District Court concluded that Clemens’s risk of future harm was not imminent, but “speculative,” because she had not yet experienced actual identity theft or fraud. J.A. 9-11. This conclusion also meant that any money Clemens spent to mitigate the speculative risk was likewise insufficient to confer standing.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
48 F.4th 146, Counsel Stack Legal Research, https://law.counselstack.com/opinion/jennifer-clemens-v-execupharm-inc-ca3-2022.